Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
23 hedge funds and large institutions have $187M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
3% more capital invested
Capital invested by funds: $182M → $187M (+$4.68M)
4% less funds holding
Funds holding: 24 → 23 (-1)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$23.1M |
| 2 |
AIP
Almanack Investment Partners
Wayne,
Pennsylvania
|
+$7.75M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$2.76M |
| 4 |
Millennium Management
New York
|
+$753K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$87.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$867K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$539K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$139K |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$72.2K |
| 5 |
FO
FT Options
Chicago,
Illinois
|
-$49K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Acadian Asset Management
Boston,
Massachusetts
| – | -$24K | -8 | Closed |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| – | -$6K | -2 | Closed |
|
|
NFG
28
Next Financial Group
Houston,
Texas
| – | -$1K | – | – |
|
NBRV Hedge Fund Activity: Q2 2017 in Review
23 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q2 2017, worth a combined $187M — up 2.6% from $182M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NBRV and 2 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was OrbiMed, adding an estimated $23.1M. The largest seller was Tekla Capital Management, cutting an estimated $867K.
- 23 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q2 2017, down from 24 in Q1 2017.
- Funds reported $187M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q2 2017, up 2.6% quarter-over-quarter.
- 2 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q2 2017 and 3 closed out, a net change of -1 holder.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q2 2017 was OrbiMed, an estimated $23.1M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q2 2017 was Tekla Capital Management, an estimated $867K sold.
Based on aggregated 13F filings for Q2 2017.